October 20, 2020
The abstract titled "Novel Dual MTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity And Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer", has been accepted for virtual presentation (Abstract #17055) at Scientific Sessions 2020 November 13-17. For a copy of the poster, please email firstname.lastname@example.org.
April 26, 2020
Late Breaking Research titled: "Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model" to be presented as an E-Poster (Tumor Biology 2, Abstract# 10226) at the Virtual AACR 2020 Annual Meeting. For a copy of the poster, please email email@example.com.
NovoMedix is the recipient of an Phase I SBIR Grant funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (award Number R43HL147726) titled: Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC..
The abstract titled “Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-induced Cardiotoxicity” has been accepted for a Rapid Fire Oral Presentation in American Heart Association Scientific Sessions on November 17, 2019.
Publication in American Journal of Physiology Heart and Circulatory Physiology Titled "A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure” highlights NovoMedix’s novel antifibrotic therapeutic program that effectively prevents cardiac fibroblast activation and preserved cardiac function in a murine model of transaortic constriction induced heart failure. The unique biological activities of these compounds should have significant impact not only in heart failure but in fibrotic disease that affect other major organs such as liver, lung, and kidney as well as malignant tumors that are highly dependent on the stroma such as pancreatic and breast cancer.